As a negative regulator, GABARAP inhibits the activities of breast cancer via regulation of the EMT, which establishes the value and significance of GABARAP as an underlying target for therapies of the multi-level progression of the specific cancer. The gene discussed is GABARAP; the disease is breast carcinoma.